Geographic atrophy
Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment
Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy ...
Apellis’ GA Drug Syfovre Displays Signs of Recovery Amid Challenges
Apellis Pharmaceuticals, which recently faced workforce reductions due to concerns surrounding its groundbreaking geographic atrophy (GA) drug, Syfovre, is reporting ...
Astellas claims positive results for Izervay in geographic atrophy but remains vague on data
Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...
Novartis drops Gyroscope’s gene therapy for eye disease after disappointing trial results
Novartis is in the process of divesting its eye disease unit, a move that includes discontinuing a geographic atrophy (GA) ...
Apellis Investigates Needle Issues Amid Search for Syfovre’s Side Effect Origins
Apellis, a pharmaceutical company, is zeroing in on a possible source of a rare but severe side effect associated with ...
FDA Approves Izervay for Geographic Atrophy
Source – Astellas Pharma Astellas Pharma has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic ...
Apellis’ Syfovre Linked to Eye Inflammation in Geographic Atrophy Patients
Source – Apellis Pharmaceuticals July 17, After receiving FDA approval for the treatment of advanced eye disease geographic atrophy, Apellis ...
